Effect of FK506 eye drops on late and delayed-type responses in ocular allergy models

Clinical and Experimental Allergy

Volumn 33, Issue 11, 2003, Pages 1555-1560

  Sengoku, T ^a   Sakuma, S ^a   Satoh, S ^a   Kishi, S ^a   Ogawa, T ^a   Ohkubo, Y ^a   Mutoh, S ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Allergic conjunctivitis; Corticosteroids; Delayed type hypersensitivity; FK506 eye drops; Guinea pigs; Late response; Ocular allergy models; Rabbits; Rats

Indexed keywords

BETAMETHASONE SODIUM PHOSPHATE; EYE DROPS; FLUOROMETHOLONE; TACROLIMUS;

ALLERGIC CONJUNCTIVITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL INFILTRATION; CHEMOSIS; CONTROLLED STUDY; DRUG EFFECT; EOSINOPHIL; GUINEA PIG; HYPEREMIA; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; RAT; SENSITIZATION; T LYMPHOCYTE;

ANIMALS; CONJUNCTIVITIS, ALLERGIC; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; EOSINOPHILS; GLUCOCORTICOIDS; GUINEA PIGS; HYPERSENSITIVITY, DELAYED; IMMUNOSUPPRESSIVE AGENTS; MALE; OPHTHALMIC SOLUTIONS; RABBITS; RATS; RATS, INBRED BN; T-LYMPHOCYTES; TACROLIMUS;

EID: 0242628968     PISSN: 09547894     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2222.2003.01698.x     Document Type: Article

References (27)

1. Bielory L, Frohman LP. Allergic and immunologic disorders of the eye. J Allergy Clin Immunol 1992; 89:1-15.
2. Bonini S, Bonini S, Vecchione A et al. Inflammatory changes in conjunctival scrapings after allergen provocation in humans. J Allergy Clin Immunol 1988; 82:462-9.
3. Tabbara KF. Ocular complications of vernal keratoconjunctivitis. Can J Ophthalmol 1999; 34:88-92.
4. Maggi E, Biswas P, Del Prete G et al. Accumulation of Th-2-like helper T cells in the conjunctiva of patients with vernal conjunctivitis. J Immunol 1991; 146:1169-74.
5. Metz DP, Bacon AS, Holgate S, Lightman SL. Phenotypic characterization of T cells infiltrating the conjunctiva in chronic allergic eye disease. J Allergy Clin Immunol 1988; 98:686-96.
6. Foster CS. The pathophysiology of ocular allergy: current thinking. Allergy 1995; 50:6-9.
7. Buckley RJ. Allergic eye disease - a clinical challenge. Clin Exp Allergy 1998; 6:39-43.
8. Bartlett JD, Woolley TW, Adams CM. Identification of high intraocular pressure responders to topical ophthalmic corticosteroids. J Ocul Pharmacol 1993; 9:35-45.
9. Kino T, Hatanaka H, Hashimoto M et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot 1987; 40:1249-55.
10. Nakagawa H, Etoh T, Ishibashi Y et al. Tacrolimus ointment for atopic dermatitis. Lancet 1994; 344:883.
11. Aoyama H, Tabata N, Tanaka M, Uesugi Y, Tagami H. Successful treatment of resistant facial lesions of atopic dermatitis with 0.1% FK506 ointment. Br J Dermatol 1995; 133:494-6.
12. Ruzicka T, Bieber T, Schöpf E et al. A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. N Engl J Med 1997; 337:816-21.
13. Andersson J, Nagy S, Groth CG, Andersson U. Effects of FK506 and cyclosporin A on cytokine production studied in vitro at a single-cell level. Immunology 1992; 75:136-42.
14. Rao A. NF-Atp: a transcription factor required for the co-ordinate induction of several cytokines genes. Immunol Today 1994; 15:274-81.
15. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol Today 1992; 13:136-42.
16. Sakuma S, Higashi Y, Sato N et al. Tacrolimus suppressed the production of cytokines involved in atopic dermatitis by direct stimulation of human PBMC system (comparison with steroids). Int Immunopharmacol 2001; 1:1219-26.
17. Sengoku T, Morita K, Sakuma S, Motoyama Y, Goto T. Possible inhibitory mechanism of FK506 (tacrolimus hydrate) ointment for atopic dermatitis based on animal models. Eur J Pharmacol 1999; 379:183-9.
18. de Paulis A, Stellato C, Cirillo R et al. Anti-inflammatory effect of FK-506 on human skin mast cells. J Invest Dermatol 1992; 99:723-8.
19. Redrup AC, Howard BP, MacGlashan DW Jr et al. Differential regulation of IL-4 and IL-13 secretion by human basophils. Their relationship to histamine release in mixed leukocyte cultures. J Immunol 1998; 160:1957-64.
20. Sengoku T, Kishi S, Sakuma S, Ohkubo Y, Goto T. FK506 inhibition of histamine release and cytokine production by mast cells and basophils. Int J Immunopharmacol 2000; 22: 189-201.
21. Calder VL, Jolly G, Hingorani M et al. Cytokine production and mRNA expression by conjunctival T-cell lines in chronic allergic eye disease. Clin Exp Allergy 1999; 29:1214-22.
22. Secchi AG, Tognon MS, Leonardi A. Topical use of cyclosporine in the treatment of vernal keratoconjunctivitis. Am J Ophthalmol 1990; 110:641-5.
23. Keightley MC, Curtis AJ, Chu S, Fuller PJ. Structural determinants of cortisol resistance in the guinea pig glucocorticoid receptor. Endocrinology 1998; 139:2479-85.
24. Sher ER, Leung DY, Surs W et al. Steroid-resistant asthma. Cellular mechanisms contributing to inadequate response to glucocorticoid therapy. J Clin Invest 1994; 93:33-9.
25. Adcock IM, Lane SJ, Brown CR et al. Differences in binding of glucocorticoid receptor to DNA in steroid-resistant asthma. J Immunol 1995; 154:3500-5.
26. Corrigan CJ, Bungre JK, Assoufi B et al. Glucocorticoid resistant asthma: T-lymphocyte steroid metabolism and sensitivity to glucocorticoids and immunosuppressive agents. Eur Respir J 1996; 9:2077-86.
27. Bleik JH, Tabbara KF. Topical cyclosporine in vernal keratoconjunctivitis. Ophthalmology 1991; 98:1679-84.